239 results about "Macular degeneration" patented technology

An engineered polypeptide for use in treating age-related macular degeneration (AMD) comprising FHL-1 engineered variant peptides, compositions including these engineered polypeptides and methods of using them. Further, wherein polypeptides include a linker domain separating the first peptide sequence from the second peptide sequence, a first junction region between the first peptide sequence and the linker domain and a second junction region between the second peptide sequence and the linker domain.

Systems and methods relate to processing optical tomography coherence (OCT) images to predict characteristics of a treatment to be administered to effectively treat age-related macular degeneration. The processing can include pre-processing the image by flattening and / or cropping the image and processing the pre-processed image using a neural network. The neural network can include a deep convolutional neural network. An output of the neural network can indicate a predicted frequency and / or interval at which a treatment (e.g., anti-vascular endothelial growth factor therapy) is to be administered so as to prevent leakage of vasculature in the eye.

The present invention relates to a novel lipid compound for tissue-specific delivery, and a lipid nano-particle (LNP) composition comprising the same, the lipid nano-particle comprising a modified lipid compound as a component, according to the present invention, internal active substances are selectively delivered into cells of specific tissues such as lymph nodes, spleen, retina, cancer, brain, liver and the like in vivo, thereby preventing side effects and safely exhibiting a desired level of effect. The tissue-specific non-viral LNP delivery vectors can be effectively used for prevention of infectious diseases and treatment of rare and refractory (hereditary) diseases (diseases which are effectively and selectively delivered to in-vivo targeted sites, such as macular degeneration, diabetic retinal degeneration, hereditary retinal degeneration, cancer, cerebral diseases, liver diseases and the like).

A classification method and a classification device for classifying a level of an age-related macular degeneration are provided. The classification method includes the following. An object detection model and a first classification model are pre-stored. A fundus image is obtained. A bounding box is generated in the fundus image according to a macula in the fundus image detected by the object detection model. An intersection over union between a predetermined area and the bounding box in the fundus image is calculated. A classification of the fundus image is generated according to the first classification model in response to the intersection over union being greater than a threshold.

Described herein are compositions and methods for treatment of Age-related Macular Degeneration (AMD). In particular, described herein are polypeptides comprising helical structures having ATP binding cassette transporter membrane stabilization and agonist activity, transporter protein binding activity, and / or that may result in a cholesterol efflux, as well as methods of using these peptides to treat AMD.

By constructing an age-related macular degeneration animal model, experimental results in multiple aspects of clinical examination (FFA and ERG), pathological detection (RPE-choroidal patch IB4 fluorescent staining) and the like prove that the rucotinib can be used for effectively treating age-related macular degeneration, especially wet age-related macular degeneration.

The present invention provides antagonizing antibodies that bind to complement factor D (CFD), conjugates thereof, and methods of using same. The anti-CFD antibodies can be used therapeutically alone or in combination with other therapeutics to treat age related macular degeneration and other diseases.

The invention relates to the technical field of drug delivery, and discloses a multilayer drug-loaded microsphere for intraocular sustained-release therapy and a preparation process thereof.The multilayer drug-loaded microsphere comprises a core layer, a middle layer and a shell layer, the core layer is composed of a polylactic acid-glycolic acid copolymer (PLGA) and a first hydrophobic drug, the middle layer is formed by wrapping the core layer with carboxymethyl chitosan, and the shell layer is composed of a first hydrophobic drug and a second hydrophobic drug. The first hydrophobic drug comprises a first therapeutic drug, the middle layer comprises a second therapeutic drug, the shell layer is composed of a polylactic acid-caprolactone copolymer PLCL and a third hydrophilic drug, and the first hydrophobic drug, the second therapeutic drug and the third hydrophilic drug are different from one another. Through the layered design of the core layer, the middle layer and the shell layer and in combination with differential degradation rates of PLGA, carboxymethyl chitosan and PLCL materials, gradient release of hydrophobic and hydrophilic drugs is achieved, a drug release curve is matched with the pathological stage of intraocular diseases, macular degeneration rapidly inhibits vascular leakage in the early stage and continuously resists inflammation in the later stage, and the effect of treating macular degeneration is achieved. And the layered slow-release synergistic treatment effect is verified.

A method and system delivers customizable microcurrent stimulation to ocular tissue using a three half-bridge driver circuit. The system includes a control circuit that selectively switches high-side and low-side transistors, such as MOSFETs, to generate various electrical waveforms, such as stepped, asymmetric biphasic, pulsed, and triangular waveforms. These waveforms are applied to electrodes in contact with the eye for therapeutic treatment, addressing conditions like age-related macular degeneration (AMD) and other ocular disorders. The system allows for adjustments in amplitude, frequency, and duration of the waveforms, providing personalized treatment protocols tailored to patient-specific needs. High-impedance periods are included between pulses to promote tissue recovery and enhance patient comfort. Additionally, a non-transitory computer-readable storage medium stores a program that controls the system, enabling real-time waveform generation and dynamic adjustment during treatment. This approach offers a flexible and efficient solution for ocular therapy, improving both treatment outcomes and patient experience.

Illustrative methods and devices for providing stimulus to the eye to treat vision disorders. Systems and methods for testing thresholds and configuring the stimulation for a patient are provided. Various examples may include therapies for vision disorders that can progress to blindness, such as macular degeneration or other diseases and disease processes.

Provided herein are screening methods and animal models relevant to ocular diseases such as age-related macular degeneration (AMD), e.g., for use in identifying candidate therapeutics for treating or preventing ocular diseases such as AMD. Also provided herein are compounds / compositions useful for killing or inhibiting the growth of microorganisms such as Bacillus megaterium. Further provided herein are methods of using the compounds / compositions to treat infections with microorganisms such as Bacillus megaterium, as well as to treat or prevent diseases or conditions associated with such infections, such as AMD.

The invention relates to the glasses industry, and aims to provide a lens structure for assisting eye disease rehabilitation by filtering and a manufacturing method thereof. A traditional lens is mainly used for correcting ametropia, and on the basis, by changing the filtering permeability of the lens, the filter lenses with different colors are used for filtering light rays with different wavelengths, the light rays act on fundus cells, the functions of the fundus cells are affected, and the effects of protection and auxiliary treatment of eye diseases are achieved. Yellow, tawny, gray, red and Finnish green filter lenses and sleep-aiding blue lenses (10%-30% of dyed lenses) are specifically designed. Lenses with different colors have unique filtering characteristics and can play a role in different eye diseases, for example, a light yellow lens is added to amblyopia to accelerate rehabilitation, and a brown lens is added to macular degeneration to suppress disease development. Meanwhile, the invention further provides a lens manufacturing method which comprises the steps of adding a color matching standard, carrying out standard operation on a dyeing heating process and the like, and the lens chromatic aberration is controlled in the horizontal direction so as to ensure the lens quality and the filtering effect.

Based on co-drugs representing two different chemical entities and the co- and sequential administration of the two chemical entities, novel therapies for macular degeneration and TTR amyloidosis are provided. The first component (“selective TTR ligand”) is a chemical entity that binds to TTR in the RBP4 (retinol-binding protein 4)-TTR (transthyretin) complex, which participates in the delivery of retinol to the retina. This component reduces retinol transport from circulation to the retina and provides stabilization of the TTR tetramer. The second component (“C20-D3-visual chromophore-generating compound”) is a C20-D3 modified retinoid or carotenoid that, when metabolized in mammals, ultimately produces a C20-D3 visual chromophore, which is presented in the retina as C20-D3-9-cis-retinal or C20-D3-11-cis-retinal. Deuteration at C20 reduces the formation of lipofuscin biretinol, but other functions (such as providing a precursor for the synthesis of the visual chromophore 11-cis-retinaldehyde in vivo) are not reduced.

The invention discloses a diisoprene derivative as shown in a structural general formula (I) and a structural general formula (II), or pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, the diisoprene derivative has the activity of regulating the expression of a low-density lipoprotein receptor (LDLR), and can inhibit tumor cell proliferation, control inflammatory factor release, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation and inhibit tumor cell proliferation. The accumulation of retinal lipofuscin is reduced, macular degeneration is improved, and retinal injury is relieved. The diisoprene derivative can be used for treating diseases related to abnormal lipid metabolism, such as cardiovascular diseases, metabolic diseases, cancer, inflammation, retinal diseases and / or other diseases. # imgabs0 #

The invention provides methods, compositions, and kits containing a first therapeutic agent that is a substituted 2,3-dimethoxyquinone of Formula I, a compound of Formula II, or a pharmaceutically acceptable salt thereof, for treating and / or preventing the progression of intermediate age-related macular degeneration and / or other conditions.

The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and / or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and / or prophylaxis of diseases, especially for treatment and / or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.

The invention provides a nanoparticle penetrating cornea as well as a preparation method and application thereof. The nanoparticle comprises a cationic liposome G2-C14, an inner core formed by aliphatic polyester and an amphiphilic polymer, and a shell modified by polysaccharide, the hydrophobic drug and the siRNA are loaded in the inner core. According to the nano-particles provided by the invention, through polysaccharide surface modification, ocular surface adhesion and trans-epithelium transport capability are enhanced, multi-barrier penetration of the eye is realized, the nano-particles are effectively delivered to a focus area of posterior segment of the eye, the delivered siRNA targets to silence the expression of age-related macular degeneration pathogenic genes, and the hydrophobic drug removes active oxygen and inhibits release of inflammatory factors, so that the anti-aging effect of the nano-particles is improved. The focus thickness is synergistically reduced.

The application discloses an AMD efficacy prediction method, system, device and medium based on feature fusion, belongs to the technical field of efficacy prediction, and comprises the following steps: acquiring optical coherence tomography image data and demographic characteristics of an age-related macular degeneration patient; determining deep learning features and imaging features according to the optical coherence tomography image data; performing feature selection based on the deep learning features, the imaging features and the demographic characteristics to obtain input features; performing calculation by combining a time series analysis network with the input features to determine a hidden state; and performing feature change trend analysis according to the hidden state to determine an age-related macular degeneration efficacy prediction result. The application proposes a multi-feature fusion long short-term memory network, and realizes efficacy prediction of anti-vascular endothelial growth factor treatment for the age-related macular degeneration patient.

Disclosed are direct-binding dual hypoxia-inducible factor (HIF) inhibitors and their use for treating cancer, including, but not limited to, breast, colorectal, lung, melanoma, pancreatic, and prostate cancer as a monotherapy and in combination with anti-CTLA-4 or anti-PD-1 immunotherapies. The dual HIF inhibitors also can be used for treating diseases, disorders, or conditions associated with ocular neovascularization, including, but not limited to, diabetic macular edema, diabetic retinopathy, and other ischemic retinopathies (including, but not limited to retinal vein occlusion, sickle cell retinopathy, retinopathy of prematurity, Norrie's disease, and Coat's disease), corneal neovascularization, and the treatment or prevention of neurovascular (wet-type) age-related macular degeneration.

To provide a deep neural network framework for processing OCT images to predict treatment intensity.SOLUTION: Systems and methods relate to processing optical tomography coherence (OCT) images to predict characteristics of treatment to be administered to effectively treat age-related macular degeneration. The processing may include pre-processing the image by flattening and / or cropping the image (230), and processing the pre-processed image using a neural network (235). The neural network may include a deep convolutional neural network. An output of the neural network can indicate a predicted frequency and / or interval at which treatment (e.g., anti-vascular endothelial growth factor therapy) is to be administered so as to prevent leakage of vasculature in the eye (240).SELECTED DRAWING: Figure 2

This invention relates to pharmaceutical compositions and methods for treatment of ophthalmic or ocular diseases and conditions. The compositions contain targeting molecules that are made up of a bifunctional hepatoma-derived growth factor-specific antibody covalently attached to a trapper that specifically binds vascular endothelial growth factor and / or transforming growth factor beta. Specific eye conditions that can be beneficially affected by the compositions and methods of the invention include age-related macular degeneration, diabetic retinopathy, peripheral vitreoretinopathy, and retinal vein occlusion.

The present invention relates to inhibitors, compositions containing inhibitors, and their use in the treatment or prevention of age-related macular degeneration (AMD).

The invention concerns a contact lens (1 ) comprising: - a lens body (10) having an optical centre (O) and an optical axis (OA) passing through the optical centre, - a prismatic element (20) intersecting with the optical axis of the lens body so as to enable a deflection of the light along with a deflection axis (A), - a counterweight (30) arranged to keep a gravity centre (GL) of the lens at a stable equilibrium point when the contact lens (1 ) is turned around the optical axis to make sure that the deflection axis reaches the target zone (C) of the retina of the patient.

The present invention relates to a novel complement C5-binding antibody and a use thereof. The complement C5-binding antibody according to the present invention can significantly inhibit complement C5 activity by targeting the MG1 domain of the beta chain of complement C5, and thus can be used for preventing or treating various complement-related diseases including myasthenia gravis, age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria.

The invention belongs to the technical field of seaweed functional products, and particularly relates to fucoidin as well as a preparation method and application thereof, in particular to application of the fucoidin in food and preparation of medicines for adjuvant treatment of age-related maculopathy. According to the invention, alginate lyase is adopted to carry out enzymolysis on seaweed, and the fucoidin with the molecular weight of 20-60 kDa is obtained after treatment of multi-stage alcohol precipitation, hydrogen peroxide degradation and membrane interception. Experimental results show that the fucoidin has the effect of repairing retinal cells, can effectively improve maculopathy, can be used for preparing related products for treating age-related macular degeneration, and provides safer natural material support for treatment of age-related macular degeneration.

Disclosed herein are mesoporous ceria nanoparticles for the prevention, treatment, or alleviation of ophthalmic diseases. In one aspect, having mesoporous structure with high surface area and pore size and mimicking the catalytic properties of catalase and superoxide dismutase (SOD), the mesoporous ceria nanoparticles of the present invention have excellent ability to scavenge reactive oxygen species, exhibit anti-inflammatory effects, demonstrate biocompatibility without causing acute side effects or ocular toxicity in the retina, and are recognized to provide protective effects against cellular damage and protect damaged retinal pigment epithelial (RPE) cells and photoreceptors under high oxidative stress. Therefore, the nanoparticles can be utilized for the prevention, treatment, or alleviation of macular degeneration and various oxidative stress-mediated ophthalmic diseases.

Illustrative methods and devices for providing stimulus to the eye to treat vision disorders. Systems and methods for feedback relating to the stimulus itself as well as the effect of such stimulus on the patient are provided. Various examples may include therapies for vision disorders that can progress to blindness, such as macular degeneration or other diseases and disease processes.

Benzyl derivative compounds having peroxisome proliferator-activated receptor alpha (PPARα) agonist activity, kits and compositions containing such compounds, and methods of using them to enhance PPARα activity to treat diseases and / or conditions involving inflammation and / or angiogenesis, particularly diseases and / or conditions of the eye such as, but not limited to, retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration, and diabetic macular edema.

A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and / or 12 weeks.